Arctic Vision Announces Completion of Over US$100 Million Series B Financing to Accelerate Portfolio Expansion, Clinical Development and Commercialization
News provided by
Share this article
Share this article
SHANGHAI, March 9, 2021 /PRNewswire/ Arctic Vision, a China-based clinical-stage ophthalmology company focused on developing innovative therapies for pan-ocular diseases, today announced the completion of over US$100 million Series B financing. The Series B round was led by Loyal Valley Capital, with participation from Tencent, Octagon Capital, and Dr. Adrian Cheng, renowned entrepreneur from New World Development Group, along with existing investors Nan Fung Life Sciences, Pivotal bioVenture Partners China and Morningside Ventures. The proceeds will continue to support the progress of Arctic Vision s pipeline, including clinical developments, registrational activities, and commercialization; as well as the establishment of in-house R&D capabilities; business development,
Chinese ophthalmology firm Arctic Vision snags over $100m in Series B round
dealstreetasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dealstreetasia.com Daily Mail and Mail on Sunday newspapers.
Arctic Vision Announces Completion of Over US$100 Million Series B Financing to Accelerate Portfolio Expansion, Clinical Development and Commercialization
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
News provided by
Share this article
SHANGHAI, Jan. 9, 2021 /PRNewswire/
VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China, announced today the closing of a $150 million Series B financing.
The round was led by Sequoia China with participation from OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as all of the existing investors, including Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments. Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong foundation for commer